Endometrial cancer, with dostarlimab in the first line

Tumore dell’endometrio, con dostarlimab in prima linea rischio di morte ridotto fino al 30%

#Endometrial #cancer #dostarlimab #line

“PharmaStarTV”

The first-line treatment of advanced/recurrent endometrial cancer is making great progress thanks to immunotherapy with dostarlimab, based on the results of a very important study, the RUBY study. The first results of this trial were published in 2023 on…

source